| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Jul―17 |
Development of potent remdesivir derivative against SARS-CoV-2 protease inhibitors: Design, modification, molecular modeling and MD simulations |
|
| 2 |
[GO] |
2026―Jul―17 |
SARS-CoV-2 infection pattern, transmission and treatment: Multi-center study in low to middle-income districts hospitals in Punjab, Pakistan |
|
| 3 |
[GO] |
2026―Jul―17 |
Effect of garlic essential oil in 97 patients hospitalized with covid-19: A multi-center experience |
|
| 4 |
[GO] |
2026―Jul―17 |
Frequency of thrombocytopenia in severe COVID-19 pneumonia and its effects on clinical outcomes |
|
| 5 |
[GO] |
2026―Jul―17 |
De novo design of novel spike glycoprotein inhibitors using e-pharmacophore modeling, molecular hybridization, ADMET, quantum mechanics and molecular dynamics studies for COVID-19 |
|
| 6 |
[GO] |
2026―Jul―16 |
In vitro evaluation of antiviral activity of Sisybrium irio (Khaksi) against SARS-COV-2 |
|
| 7 |
[GO] |
2026―Jul―16 |
Early forecasting of COVID-19 case progression with hematological and biochemical parameters of patients in Egypt |
|
| 8 |
[GO] |
2026―Jul―15 |
Colorimetric chromophoric rapid detection of SARS-CoV-2 through breath analysis |
|
| 9 |
[GO] |
2026―Jul―15 |
Forecasting the daily deaths caused by COVID-19 using ARIMA model |
|
| 10 |
[GO] |
2026―Jul―07 |
Review: Novel Coronavirus-2019 (2019-nCoV): Perspectives of emergence, prophylaxis and predicted treatment approaches |
|
| 11 |
[GO] |
2026―Jul―01 |
Working capital management: Analysis of profitability during the Covid -19 pandemic of multinational and local pharmaceutical companies of Pakistan |
|
| 12 |
[GO] |
2026―Jul―01 |
Effect of COVID-19 vaccination on menstrual cycle irregularities among females: A cross-sectional study in Pakistan |
|
| 13 |
[GO] |
2026―Jan―10 |
The Impact Of Non-Pharmaceutical Interventions On The Epidemiological Characteristics And Macrolide Resistance Of Mycoplasma Pneumoniae Infection In Children During COVID-19 In Single Centre |
|
| 14 |
[GO] |
2025―Aug―27 |
Possible neglected transient (T) polyagglutination in critically ill patients with coronavirus disease-2019 (Covid-19) |
|
| 15 |
[GO] |
2025―Aug―18 |
Predicting SARS-CoV-2 Omicron Outcomes: Investigating The Relationship Of TLC, Ferritin, D-Dimer, LDH, C-Reactive Protein And HbA1c |
|
| 16 |
[GO] |
2025―Jun―27 |
Drug-Drug Interactions With Azithromycin During COVID-19: An Evidence Of Contribution Towards Patient Mortality |
|
| 17 |
[GO] |
2021―Jan―24 |
In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19 |
|
| 18 |
[GO] |
2020―Dec―27 |
Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15 |
|
| 19 |
[GO] |
2020―Dec―27 |
Observation on China's efficient mobilization and external dependencies in COVID-19 detection reagents, vaccines and drugs development |
|
| 20 |
[GO] |
2020―Dec―27 |
QadirVID-19: A fusion inhibitor against Novel Coronavirus-2019 for specific management of COVID-19 |
|
| 21 |
[GO] |
2020―Dec―20 |
Review: Herbs, Immunity and nCOVID-19: Old performers in new Pandemic |
|
| 22 |
[GO] |
2020―Dec―20 |
Treatment and control strategies for COVID-19: Prospects and possibilities |
|
| 23 |
[GO] |
2020―Dec―20 |
Causes And Treatment Of Covid-19: Myths Vs Facts |
|
| 24 |
[GO] |
2020―Dec―20 |
Emerging pharmacy services: Recommendations for emergency care of COVID-19 pandemic in low and middle-income countries |
|
| 25 |
[GO] |
2020―Dec―20 |
Impact of COVID-19 in public health: Prevalence and preventive approaches |
|
